Hydrochloric Acid → (1R, 5S, 6S)-2-[(2S, 4S)-2-(4-Acetimidoylpiperazin-1-ylcarbonyl)pyrrolidin-4-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylic acid hydrochloride

HRID 361997노트

반응식

HRID 361997 반응식
[C:1]([N:4]1[CH2:9][CH2:8][N:7]([C:10]([C@@H:12]2[CH2:16][C@H:15]([S:17][C:18]3[C@H:19]([CH3:32])[C@@H:20]4[C@@H:27]([C@H:28]([OH:30])[CH3:29])[C:26](=[O:31])[N:21]4[C:22]=3[C:23]([OH:25])=[O:24])[CH2:14][NH:13]2)=[O:11])[CH2:6][CH2:5]1)(=[NH:3])[CH3:2].[ClH:33]>O>[ClH:33].[C:1]([N:4]1[CH2:5][CH2:6][N:7]([C:10]([C@@H:12]2[CH2:16][C@H:15]([S:17][C:18]3[C@H:19]([CH3:32])[C@@H:20]4[C@@H:27]([C@H:28]([OH:30])[CH3:29])[C:26](=[O:31])[N:21]4[C:22]=3[C:23]([OH:25])=[O:24])[CH2:14][NH:13]2)=[O:11])[CH2:8][CH2:9]1)(=[NH:3])[CH3:2]

참가 물질

4

실험 절차

200 mg of (1R, 5S, 6S)-2-[(2S, 4S)-2-(4-acetimidoylpiperazin-1-ylcarbonyl)pyrrolidin-4-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylic acid [prepared as described in step (b) above] were dissolved in 5 ml of water, after which 0.43 ml of 1N aqueous hydrochloric acid was added. The resulting mixture was worked up and purified by reverse phase column chromatography through 30 ml of Cosmo Sil 75C18 -PREP (a trade mark for a product of Nacalai Tesque), using water as the eluent. Those fractions containing the title compound were combined and lyophilized to give 149 mg of the title compound as a powder.

후처리

  1. custompurified by reverse phase column chromatography through 30 ml of Cosmo Sil 75C18 -PREP (a trade mark for a product of Nacalai Tesque),
  2. additionThose fractions containing the title compound

출처 및 근거

ORD 기록
ord-96c7b297465341e885620edf08304a28
출처 데이터셋
uspto-grants-1999_02
특허 번호
US05866564

반응 노트

불러오는 중…